Get Cash Back and $0 Commissions + The Power of TradeStation
Consolidated Research: 2019 Summary Expectations for TherapeuticsMD, Ensco plc, Cray, BeiGene, The Gap, and Nordson Fundamental Analysis, Key Performance Indications
Globe Newswire 5-Mar-2019 8:35 AM
NEW YORK, March 05, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of TherapeuticsMD, Inc. (NASDAQ:TXMD), Ensco plc (NYSE:ESV), Cray Inc (NASDAQ:CRAY), BeiGene, Ltd. (NASDAQ:BGNE), The Gap, Inc. (NYSE:GPS), and Nordson Corporation (NASDAQ:NDSN), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.
Complimentary Access: Research Reports
Full copies of recently published reports are available to readers at the links below.
(You may have to copy and paste the link into your browser and hit the [ENTER] key)
The new research reports from Capital Review, available for free download at the links above, examine TherapeuticsMD, Inc. (NASDAQ:TXMD), Ensco plc (NYSE:ESV), Cray Inc (NASDAQ:CRAY), BeiGene, Ltd. (NASDAQ:BGNE), The Gap, Inc. (NYSE:GPS), and Nordson Corporation (NASDAQ:NDSN) on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. Several excerpts from the recently released reports are available to today's readers below.
-----------------------------------------
Important Notice: the following excerpts are not designed to be standalone summaries and as such, important information may be missing from these samples. Please download the entire research report, free of charge, to ensure you are reading all relevant material information. All information in this release was accessed March 1st, 2019. Percentage calculations are performed after rounding. All amounts in millions (MM), except per share amounts.
-----------------------------------------
THERAPEUTICSMD, INC. (TXMD) REPORT OVERVIEW
TherapeuticsMD's Recent Financial Performance
For the three months ended September 30th, 2018 vs September 30th, 2017, TherapeuticsMD reported revenue of $3.47MM vs $4.42MM (down 21.37%) and analysts estimated basic earnings per share -$0.16 vs -$0.07. For the twelve months ended December 31st, 2017 vs December 31st, 2016, TherapeuticsMD reported revenue of $16.78MM vs $19.36MM (down 13.32%) and analysts estimated basic earnings per share -$0.37 vs -$0.46. Analysts expect earnings to be released on May 2nd, 2019. The report will be for the fiscal period ending March 31st, 2019. The reported EPS for the same quarter last year was -$0.11. The estimated EPS forecast for the next fiscal year is -$0.06 and is expected to report on February 20th, 2020.
For the three months ended September 30th, 2018 vs September 30th, 2017, Ensco plc reported revenue of $430.90MM vs $460.20MM (down 6.37%) and analysts estimated basic earnings per share -$0.33 vs -$0.08. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Ensco plc reported revenue of $1,843.00MM vs $2,776.40MM (down 33.62%) and analysts estimated basic earnings per share -$0.91 vs $3.13. Analysts expect earnings to be released on April 24th, 2019. The report will be for the fiscal period ending March 31st, 2019. Reported EPS for the same quarter last year was -$0.32. The estimated EPS forecast for the next fiscal year is -$0.85 and is expected to report on February 26th, 2020.
For the three months ended December 31st, 2018 vs December 31st, 2017, Cray reported revenue of $163.36MM vs $166.64MM (down 1.97%) and analysts estimated basic earnings per share -$0.32 vs -$2.43. For the twelve months ended December 31st, 2018 vs December 31st, 2017, Cray reported revenue of $455.95MM vs $392.51MM (up 16.16%) and analysts estimated basic earnings per share -$1.76 vs -$3.33. Analysts expect earnings to be released on May 7th, 2019. The report will be for the fiscal period ending March 31st, 2019. Reported EPS for the same quarter last year was -$0.53. The estimated EPS forecast for the next fiscal year is -$0.73 and is expected to report on February 11th, 2020.
For the three months ended September 30th, 2018 vs September 30th, 2017, BeiGene reported revenue of $54.20MM vs $220.21MM (down 75.39%) and basic earnings per share -$2.53 vs $2.79. For the twelve months ended December 31st, 2017 vs December 31st, 2016, BeiGene reported revenue of $238.39MM vs $1.07MM (up 22,179.16%) and analysts estimated basic earnings per share -$2.23 vs -$3.84. Analysts expect earnings to be released on May 8th, 2019. The report will be for the fiscal period ending March 31st, 2019. The reported EPS for the same quarter last year was -$2.03. The estimated EPS forecast for the next fiscal year is -$9.13 and is expected to report on February 26th, 2020.
For the three months ended October 31st, 2018 vs October 31st, 2017, The Gap reported revenue of $4,089.00MM vs $3,838.00MM (up 6.54%) and analysts estimated basic earnings per share $0.69 vs $0.59 (up 16.95%). For the twelve months ended January 31st, 2018 vs January 31st, 2017, The Gap reported revenue of $15,855.00MM vs $15,516.00MM (up 2.18%) and analysts estimated basic earnings per share $2.16 vs $1.69 (up 27.81%). Analysts expect earnings to be released on May 23rd, 2019. The report will be for the fiscal period ending April 30th, 2019. The reported EPS for the same quarter last year was $0.42. The estimated EPS forecast for the next fiscal year is $2.63 and is expected to report on February 27th, 2020.
For the three months ended January 31st, 2019 vs January 31st, 2018, Nordson reported revenue of $497.91MM vs $550.42MM (down 9.54%) and analysts estimated basic earnings per share $0.84 vs $1.81 (down 53.59%). For the twelve months ended October 31st, 2018 vs October 31st, 2017, Nordson reported revenue of $2,254.67MM vs $2,066.98MM (up 9.08%) and analysts estimated basic earnings per share $6.51 vs $5.14 (up 26.65%). Analysts expect earnings to be released on May 20th, 2019. The report will be for the fiscal period ending April 30th, 2019. The reported EPS for the same quarter last year was $1.56. The estimated EPS forecast for the next fiscal year is $7.09 and is expected to report on December 11th, 2019.
Capital Review is a nationally recognized publisher of financial analysis, research reports, and exclusive market reporting. Institutional investors, registered brokers, professional traders, and personal investment advisers rely on Capital Review to quantify public company valuations, discover opportunity across asset classes, stay informed about market-moving events, and read exclusive analysis of important material developments. With 14 offices worldwide, Capital Review staffs and manages certified and registered financial professionals, including Chartered Financial Analyst® (CFA®) designation holders and FINRA® BrokerCheck® certified individuals with current and valid CRD® number designations, to enable continuous coverage of topics relevant to its regular active reader base.
REGISTERED MEMBER STATUS
Capital Review's oversight and audit staff are registered analysts, brokers, and/or financial advisers ("Registered Members") working within Equity Research, Media, and Compliance departments. Capital Review's roster includes qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers. Current licensed status of several Registered Members at Capital Review have been independently verified by an outside audit firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries regarding this release should be directed to Capital Review's Compliance department by Phone, at +1 (410) 280-7496, or by E-mail at compliance@Capital-Review.com.
LEGAL NOTICES
Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Capital Review, Capital Review members, and/or Capital Review affiliates are not responsible for any gains or losses that result from the opinions expressed. Capital Review makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice. Capital Review has not been compensated for the publication of this press release by any of the above mentioned companies. Capital Review is not a financial advisory firm, investment adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full disclaimer, disclosure, and terms of service please visit our website.
Media Contact: Nicole Garrens, Media Department Office: +1 (410) 280-7496 E-mail: media@Capital-Review.com
